InvestorsHub Logo
Followers 154
Posts 2652
Boards Moderated 0
Alias Born 01/29/2004

Re: oldandintheway post# 312649

Thursday, 06/03/2021 10:37:11 PM

Thursday, June 03, 2021 10:37:11 PM

Post# of 463446
But how was Aricept received?

...the free world will go nuts if (when) a-mab is approved...


Well, did that happen when Aricept got approved? The efficacy of Aricept is minor. It merely slows, for a period, the inevitable lethal progression of Alzheimer's; not a really successful treatment at all.

How will the new Biogen drug, if approved, actually compare to Aricept? Is there any evidence, is anyone touting how much better it will be, compared to Aricept?

The blarcamesine clinical data will stand by themselves. The drug's mechanism of action (MoA), unlike the other two, can provide for far better and enduring therapeutic outcomes. In time (less than a year?) the treatment stories for all three of the drugs will be known. Both clinicians and patients will prefer, opt for blarcamesine. Aricept is already a minor Alzheimer' drug of little repute. One doesn't hear of Aricept successes. There are none. The same will be story of the new Biogen drug — should it ever get approved.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News